MRUS
Subidón +60& que se ha desinflado hasta el 38%
Merus has gained close attention for its own bispecific platform and a lead drug dubbed MCLA-128, which has produced some intriguing data in a Phase I/II trial. Merus has been promising to release interim Phase II data on 128 by the end of this year. And while the data has yet to arrive publicly, an obvious question for now is whether Incyte has already seen more mature data that helped persuade it to pull the trigger on this deal.
https://endpts.com/incyte-antes-up-200m-promises-billions-more-to-launch-a-bispecific-development-deal-with-merus/
Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies
Biclonics® retain the IgG format of antibodies that are produced naturally by the immune system and, by binding to two targets, enable multiple modes of action that cannot otherwise be obtained with conventional monoclonal antibodies.
Under the terms of the collaboration, Incyte has agreed to pay Merus an upfront payment of $120 million. In addition, Incyte has agreed to purchase 3.2 million shares of Merus stock at $25 per share, for a total equity investment of $80 million.
The parties have agreed to collaborate on the development and commercialization of up to 11 bispecific antibody programs. For one current preclinical program, Merus will retain all rights to develop and commercialize approved products in the United States, and Incyte will develop and commercialize approved products arising from the program outside the United States. Following any regulatory approval of a product candidate for this particular pre-clinical program, each company has agreed to pay the other tiered royalties ranging from 6 to 10 percent on net sales of products in their respective territories.
Merus also has the option to co-fund development of product candidates arising from two other programs. For any program for which Merus exercises its co-development option, Merus would be responsible for 35 percent of global development costs in exchange for a 50 percent share of U.S. profits and losses and tiered royalties ranging from 6 to 10 percent on ex-U.S. sales by Incyte for these programs. Merus also has the right to elect to provide up to 50 percent of detailing activities for product candidates arising from one of these programs in the United States.
For each of the other eight programs, Incyte has agreed to independently fund all development and commercialization activities. For these programs, Merus will be eligible to receive potential development, regulatory and sales milestone payments of up to $350 million per program, which could result in an aggregate milestone opportunity of approximately $2.8 billion if all development, regulatory and sales milestones are achieved across all such eight other programs in all territories. Merus will also be eligible to receive tiered royalties ranging from 6 to 10 percent on global sales of any approved products under these eight programs.
Merus will retain rights to both of its clinical candidates and MCLA-158, as well as its technology platform and future programs emerging from Merus’ platform that are outside the scope of this agreement.
The transaction is expected to close in the first quarter of 2017,
http://www.abc-7.com/story/34104459/incyte-and-merus-announce-global-strategic-research-collaboration-to-discover-and-develop-bispecific-antibodies
«Después de nada, o después de todo/ supe que todo no era más que nada.»
